Drug Profile

Anti-CD19/CD20 chimeric antigen receptor T cell therapy - Hebei Senlang Biotechnology

Alternative Names: Anti-CD19/CD20 CAR-T cell therapy - Hebei Senlang Biotechnology; CD19+CD20 dual CAR-T cells - Hebei Senlang Biotechnology

Latest Information Update: 23 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hebei Senlang Biotechnology
Developer Hebei Senlang Biotechnology; Peking University People's Hospital
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

07 Jan 2026 Phase-0 for B-cell lymphoma (Second-line therapy or greater) in China (Parenteral) (NCT07344818)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com